GSK3 inhibitors: development and therapeutic potential
Abstract Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades
ago as an enzyme involved in the control of glycogen metabolism. In recent years it has
been shown to have key roles in regulating a diverse range of cellular functions, which have
prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology
of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases,
and discuss progress in the development of GSK3 inhibitors.
ago as an enzyme involved in the control of glycogen metabolism. In recent years it has
been shown to have key roles in regulating a diverse range of cellular functions, which have
prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology
of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases,
and discuss progress in the development of GSK3 inhibitors.
Abstract
Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.
nature.com